Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

Gaudet, Mia M.; Kuchenbaecker, Karoline B.; Vijai, Joseph; Klein, Robert J.; Kirchhoff, Tomas; McGuffog, Lesley; Barrowdale, Daniel; Dunning, Alison M.; Lee, Andrew; Dennis, Joe

Published in:
PLOS Genetics

DOI:
10.1371/journal.pgen.1003173

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2013

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk


1 Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America, 2 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, 3 Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 4 Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 5 Division of Epidemiology, Department of Environmental Medicine, New York University School of Medicine, New York, New York, United States of America, 6 Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom, 7 Genetics and Population Health Division, Queensland Institute of Medical Research, Brisbane, Australia, 8 Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Québec, Canada, 9 Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon-Centre Léon Bérard, Lyon, France, 10 INSERM U1052, CNRS UMR2886, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France, 11 Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, 12 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America, 13 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America, 14 Centre d’Innovation Génome Québec et Université McGill, Montreal, Québec, Canada, 15 Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands, 16 Institut Curie, Department of Tumour Biology, Paris, France, 17 Institut Curie, INSERM U830, Paris, France, 18 Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 19 Kathleen Cunningham Consortium for Research into Familial Breast Cancer–Peter MacCallum Cancer Center, Melbourne, Australia, 20 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, 21 IFOM, Fondazione Istituto FIRC di Oncologia Molleolare, Milan, Italy, 22 University Hospital of Cologne, Cologne, Germany, 23 Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 24 Department of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 25 Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York, United States of America, 26 Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, 27 Department of Clinical Genetics, Odense University Hospital, Odense, Denmark, 28 Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, 29 Center for Genomic Medicine, Righoshpitalet, Copenhagen University Hospital, Copenhagen, Denmark, 30 Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California, United States of America, 31 Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL–Catalan Institute of Oncology, Barcelona, Spain, 32 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America, 33 Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America, 34 Clinical Cancer Genetics (for the City of Hope Clinical Cancer Genetics Community Research Network), City of Hope, Duarte, California, United States of America, 35 Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, 36 Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada, 37 Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah.
United States of America, 38 Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy, 39 Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy, 40Molecular Oncology Laboratory, Hospital Clínico San Carlos, IDIISC, Madrid, Spain, 41 Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland, 42Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain, 43Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain, 44 Department of Genetics, University of Pretoria, Pretoria, South Africa, 45 Department of Pathology, Landskrona University Hospital, Röyjåviken, Sweden, 46BMF, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 47 Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Haifa, Israel, 48 Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands, 49 Department of Genetics, University Medical Center, Groningen University, Groningen, The Netherlands, 50 Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 51 Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands, 52 Department of Human Genetics and Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, 53 Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands, 54 Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands, 55 Clinical Genetics, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom, 56 Yorkshire Regional Genetics Service, Leeds, United Kingdom, 57 Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom, 58 South East Yorkshire Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom, 59 National Cancer Genetics Network, UNICANCER Genetic Group, France, 60 Cancer Genetics Unit, INSERM U916, Institut Bergonie, Université de Bordeaux, Bordeaux, France, 61 Laboratoire de Génétique Chromosomique, Hôpital Dieu Centre hospitalier, Chambéry, France, 62 Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy, 63 Division of Cancer Prevention and Genetics, Instituto Europeo di Oncologia, Milan, Italy, 64 Fioreg Foundation for Pharmacogenomics and Unit of Medical Genetics, Department of Pathophysiology, University of Florence, Florence, Italy, 65 University Hospital of Schleswig-Holstein, University Kiel, Kiel, Germany, 66 Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University, Munich, Germany, 67 University of Heidelberg, Heidelberg, Germany, 68 Sheba Medical Center, Tel Aviv, Israel, 69 Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark, 70 Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL—Catalan Institute of Oncology, Barcelona, Spain, 71 Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia, 72 Netherlands Cancer Institute, Antonie van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 73 University Breast Cancer Francia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany, 74 Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, 75 London School of Hygiene and Tropical Medicine, London, United Kingdom, 76 Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation Trust in partnership with King’s College London, London, United Kingdom, 77 Department of Obstetrics and Gynaecology, University of Heidelberg, Heidelberg, Germany, 78 Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany, 79 Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France, 80 University of Paris-Sud, UMR-S 1018, Villejuif, France, 81 Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark, 82 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany, 83 Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany, 84 University of Tubingen, Tubingen, Germany, 85 Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany, 86 Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IfA), Bochum, Germany, 87 Institute and Outpatient Clinic of Occupational Medicine, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany, 88 Institute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany, 89 Department of Internal Medicine, Evangelische Klinikum Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany, 90 Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland, 91 Department of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany, 92 Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden, 93 School of Medicine, Institute of Clinical Medicine, Pathology, and Forensic Medicine, Biocenter Kuopio, Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland, 94 Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland, 95 Vesalius Research Center, VIB, Leuven, Belgium, 96 Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Belgium, 97 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 98 Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia, 99 Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia, 100 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, 101 Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland, 102 Department of Human Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 103 Division of Genetics and Epidemiology of Breast Cancer Research, The Institute of Cancer Research, Sutton, United Kingdom, 104 Division of Breast Cancer Research, British Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom, 105 Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 106 Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands, 107 CRUK/CRY Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom, 108 Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, 109 Human Genotyping–CEGEN Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, 110 Department of Molecular Biology and Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 111 Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America, 112 Departments of Genetics and Medicine, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To continue improving our understanding of the genetic basis of breast cancer risk, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80–0.90, **P = 3.9 × 10⁻²**). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.

PLOS Genetics | www.plosgenetics.org 2 March 2013 | Volume 9 | Issue 3 | e1003173
hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland, and by the strategic funding of the University of Eastern Finland. Kathleen Cuningham Consortium for Research into Familial Breast Cancer: KcICFb is supported by grants from the National Breast Cancer Foundation and the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund; the Cancer Council Victoria, Tasmania, and South Australia; and the Cancer Foundation of Western Australia. G Chenevix-Trench and AB Spurdle are NHMRC Senior Research Fellows. Financial support for the ACCS was provided by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council of Tasmania and Cancer Foundation of Western Australia, and the NHMRC (1996600). G Chenevix-Trench is supported by the NHMRC. The Clinical Follow Up Study (funded 2006–2009) by NHMRC and currently by the National Breast Cancer Foundation. The Swedish Breast Cancer Registry (funded 1989–2013) was supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea (1020300). Leuven Multidisciplinary Breast Centre: LMBC is supported by the ‘Stichting tegn Kanker’ (232-2008 and 196-2010). D Lambrechts is supported by the FWO and the KULPVT/10/016-Symbiosis. Mammary Carcinoma Risk Factor Investigation: The MARIE study was supported by the Deutsche Krebshilfe e.V. (702-2009). Hamburg Cancer Society, the German Cancer Research Center, and the genome work performed in part by the Federal Ministry of Education and Research (BMBF) Germany [01KHO002]. Mayo Clinic: MAYO is supported by NIH grant CA129879, an NCI Specialized Program of Research Excellence (SPRE) in Breast Cancer (CA116201), a U.S. Department of Defence Ovarian Cancer Idea award (W81XWH-10-1-0341), and grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure. Milan Breast Cancer Study Group: MBCSG was funded by grants from Fondazione Italiana per la Ricerca sul Cancro Special Project “Heredity tumors”; Italian Association for Cancer Research (AIRC, IG 8713), Italian Ministry of Health (“Progetto Tumori Femminili”), and by Italian citizens who allocated the 5 × 1000 share of their tax payment in support of the Fondazione ICRCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects “5 × 1000”). Melbourne Collaborative Cohort Study: MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251335 and 304711 and by infrastructure provided by Cancer Council Victoria, McGill University: The McGill Study was supported by Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade. Multi-Ethnic Cohort: The MEC was supported by NIH grants CA63464, CA54281, CA908758, and CA132839. Memorial Sloan-Kettering Cancer Center: The MSKCC was supported by Breast Cancer Research Foundation, Niehaus Clinical Cancer Genetics Initiative, Andrew Sabin Family Foundation, and Lymphoma Foundation. Montreal Gene Environment Breast Cancer Study: The work of MLTGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program grant CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade grant PSR-SIHR-701. J Simard is Chairholder of the Canada Research Chair in Oncogenetics. National Cancer Institute: The research of MH Greene and PL Mai was supported by the Intramural Research Program of the US National Cancer Institute, NIH, and by support contracts N02-CP-11019-50 and N02-CP-65504 with Westat, Rockville, MD. National Israeli Cancer Control Center: NICCC is supported by Clalit Health Services in Israel. Some of its activities are supported by the Israel Cancer Association and the Breast Cancer Research Foundation (BCRF), New York. N. N. Petrov Institute of Oncology: The NPIIO study has been supported by the Russian Federation for Basic Research (grants 10-04-00227, 12-04-00298, and 12-04-01-4900) and the Federal Agency for Science and Innovations, Russia (contract 02.740.11.0780). Oulu Breast Cancer Study: The OBCS was supported by research funding from the Finnish Cancer Foundation, the Academy of Finland, the University of Oulu, and the Leif and Sonja Hietanen Oulu Breast Cancer Research Foundation. Medical Light Breast Centre Cancer Study: The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The Ohio State University Comprehensive Cancer Center: OSUCCG is supported by the Ohio State University Comprehensive Cancer Center. SEABASS is supported by the National Institute of Science, Technology and Innovation, Ministry of Higher Education (UM.CHR/ MEHO/06) and Cancer Research Initiatives Foundation. The U.S. National Cancer Institute Polish Breast Cancer Study: The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Karolinska Mammography Project for Risk Prediction of Breast Cancer - prevalent cases: The pKARMa study was supported by Marit and Hans Rausings Initiative Against Breast Cancer, Rotterdam Breast Cancer Study: The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). Singapore and Sweden Breast Cancer Study: The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the U.S. National Institute of Health (NIH), and the Susan G. Komen Breast Cancer Foundation. Sheffield Breast Cancer Study: The SBSC was supported by Yorkshire Cancer Research S295, S299, and S305PA. South East Asian Breast Cancer Association Study: SEABASS is supported by the National Institute of Science, Technology and Innovation, Ministry of Higher Education (UM.CHR/MEHO/06) and Cancer Research Initiatives Foundation. The Malaysian Breast Cancer Genetic Study is funded by research grants from the Malaysian Ministry of Science, Technology and Innovation; Ministry of Higher Education (UM.CHR/MEHO/06); and charitable funding from Cancer Research Initiatives Foundation. Study of Epidemiology and Risk Factors in Cancer Heredity: SEARCH is funded by programme grants from Cancer Research UK [C490/A10124/C4197/A10123]. AM Dunning was funded by [C18179/101865]. Sheba Medical Centre: The SMC study was partially funded through a grant by the Israel Cancer Association and the funding for the Israeli Inherited Breast Cancer Consortium. Swedish Breast Cancer Study: SWE-BRCA collaborators are supported by the Swedish Cancer Society. IHCCE-Siczecin Breast Cancer Study: The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. The University of Chicago Center for Clinical Genetics and Global Health: UCHICAGO is supported by grants from the U.S. National Cancer Institute (NIH/NCI) and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women’s Cancer Research Alliance, and the Breast Cancer Foundation. University of California Los Angeles: The UCLA study was supported by the Jonsson Comprehensive Cancer Center Foundation and the Breast Cancer Research Foundation. University of California San Francisco: The UCSF study was supported by the UCSF Cancer Risk Program and the Helen Diller Family Comprehensive Cancer Research Foundation. United Kingdom Breast Cancer Linkage Studies: The UKBCLS is supported by the British Heart Foundation. The UKBCLS is supported by the British Heart Foundation. The UKBCLS is supported by the British Heart Foundation. The UKBCLS is supported by the British Heart Foundation. Victorian Familial Cancer Trials Study: The VFCTG study was supported by the Victorian Cancer Agency, Cancer Australia, and the National Breast Cancer Foundation. Women’s Cancer Program: The WCP at the Samuel Oschin Comprehensive Cancer Institute is funded by the American Cancer Society Early Detection Professorship (SOP-06-258-01-COND). Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study: The study was supported by a grant from the National Cancer Foundation of Norway and the Breast Cancer “The Norwegian women’s” Award, and by the Canadian Institutes for Health Research/Canadian Cancer Society for the “CIHR Team in Familial Risks of Breast Cancer” program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: olfftk@mskcc.org

† These authors contributed equally to this work.

Introduction

The lifetime risk of breast cancer associated with carrying a BRCA2 mutation varies from 40 to 84% [1]. To determine whether common genetic variants modify breast cancer risk for BRCA2 mutation carriers, we previously conducted a GWAS of BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) [2]. Using the Affymetrix 6.0 platform, the discovery stage results were based on 899 young (<80 years) affected and 804 unaffected carriers of European ancestry. In a rapid replication stage wherein 65 discovery stage SNPs with the smallest P-values were genotyped in 2,436 additional BRCA2 mutation carriers, only published loci associated with breast cancer risk in the general population, including FGFR2 (10q26; rs2901575; P = 1.2 × 10−8), were associated with breast cancer risk at the genome-wide significance level among BRCA2 mutation carriers.
GWAS of BRCA2 Mutation Carriers

**Author Summary**

Women who carry BRCA2 mutations have an increased risk of breast cancer that varies widely. To identify common genetic variants that modify the breast cancer risk associated with BRCA2 mutations, we have built upon our previous work in which we examined genetic variants across the genome in relation to breast cancer risk among BRCA2 mutation carriers. Using a custom genotyping platform with 211,155 genetic variants known as single nucleotide polymorphisms (SNPs), we genotyped 3,881 women who had breast cancer and 4,330 women without breast cancer, which represents the largest possible, international collection of BRCA2 mutation carriers. We identified that a SNP located at 6p24 in the genome was associated with lower risk of breast cancer. Importantly, this SNP was not associated with breast cancer in BRCA1 mutation carriers or in a general population of women, indicating that the breast cancer association with this SNP might be specific to BRCA2 mutation carriers. Combining this BRCA2-specific SNP with 13 other breast cancer risk SNPs also known to modify risk in BRCA2 mutation carriers, we were able to derive a risk prediction model that could be useful in helping women with BRCA2 mutations weigh their risk-reduction strategy options.

**Materials and Methods**

**Ethics statement**

Each of the host institutions (Table S1) recruited under ethically-approved protocols. Written informed consent was obtained from all subjects.

**Study subjects**

The majority of BRCA2 mutation carriers were recruited through cancer genetics clinics and some came from population or community-based studies. Studies contributing DNA samples to these research efforts were members of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) with the exception of one study (NICCC). Eligible subjects were women of European descent who carried a pathogenic BRCA2 mutation, had complete phenotype information, and were at least 18 years of age. Harmonized phenotypic data included year of birth, age at breast cancer diagnosis, age at bilateral prophylactic mastectomy and oophorectomy, age at interview or last follow-up, BRCA2 mutation description, self-reported ethnicity, and breast cancer estrogen receptor status.

**Study subjects**

Details of these samples have been described previously [2]. Data from 899 young (<40 years) affected and 804 older (>40 years) unaffected carriers of European ancestry from 14 countries were used to select SNPs for inclusion on the iCOGS array.

**Samples genotyped in the extended replication set**

Forty-seven studies from 24 different countries (including two East-Asian countries) provided DNA from a total of 10,048 BRCA2 mutation carriers. All eligible samples were genotyped using COGs, including those from the discovery stage.

**Genotyping and quality control**

**BRCA2 SNP selection for inclusion on iCOGS.** The Collaborative Oncological Gene-Environment Study (COGS) consortium developed a custom genotyping array (referred to as the iCOGS array) to provide efficient genotyping of common and rare genetic variants to identify novel loci that are associated with risk of breast, ovarian, and prostate cancers as well as to fine-map known cancer susceptibility loci. SNPs were selected for inclusion on iCOGS separately by each participating consortium: Breast Cancer Association Consortium (BCAC) [6], Ovarian Cancer Association Consortium (OCAC) [7], Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) [8], and CIMBA. SNP lists from a BRCA1 GWAS and SNPs in candidate regions were used together with the BRCA2 GWAS lists to generate a ranked CIMBA SNP list that included SNPs with the following nominal proportions: 55.5% from the BRCA1 GWAS, 41.6% from the BRCA2 GWAS and fine mapping, 2.9% for CIMBA candidate SNPs. Each consortium was given a share of the array: nominally 25% of the SNPs each for BCAC, PRACTICAL and OCAC; 17.5% for CIMBA; and 7.5% for SNPs from commonly researched pathways (e.g., inflammation). For the CIMBA BRCA2 GWAS, we used the iCOGS array as the platform to genotype the extended replication set of the discovery GWAS stage [2]. SNPs were selected on the basis of the strength of their associations with breast cancer risk in the discovery stage [2], using imputed genotype data for 1.4 M SNPs identified through COGs, including those from the discovery stage. SNPs were selected for fine mapping of the regions surrounding the SNPs found to be associated with breast cancer in the discovery GWAS stage: rs16917302 on 10q21 and rs311499 on 20q13, including SNPs with a MAF >0.05 located 500 kb in both directions of the SNP, based on the iCOGS array comprised 220,123 SNPs. Of these, 211,155 were successfully manufactured onto the array. The present analyses are based on the 19,029 SNPs selected on the basis of BRCA2 GWAS and fine mapping that were included on the iCOGS array.

**Genotyping.** The genotyping was performed on DNA samples from 10,048 BRCA2 mutation carriers at the McGill University and Genome Quebec Innovation Centre (Montreal, Canada). As a quality control measure, each plate included DNA samples from six individuals who were members of two CEPH trios. Some plates also contained three duplicate pairs of quality control samples. Genotypes were called using GenCall [9]. Initial calling was based on a cluster file generated using 270 samples from Hapmap2. To generate the final calls, we first selected a subset of 3,018 individuals, including samples from each of the genotyping centers in the iCOGS project, each of the participating
consortia, and each major ethnicity. Only plates with a consistent high cell rate in the initial calling were used. We also included 380 samples of European, African, and Asian ethnicity genotyped as part of the Hapmap and 1000 Genomes project, and 160 samples that were known positive controls for rare variants on the array. This subset was used to generate a cluster file that was then applied to call the genotypes for the remaining samples.

Quality control of SNPs. Of the 211,155 SNPs on the iCOGS array, we excluded SNPs for the following reasons (Table S2): on the Y-chromosome, call rate <95%, deviations from Hardy-Weinberg equilibrium (P<10^{-5}) using a stratified 1-d.f. test [10], and monomorphic. SNPs that gave discrepant genotypes among known duplicates were also excluded. After quality control filtering, 200,908 SNPs were available for analysis (Table S2); 18,086 of which were selected on the basis of the discovery BCAC GWAS [2]. Cluster plots of all reported SNPs were inspected manually for quality (Figure S1).

Description of imputation. Genotypes for SNPs identified through the 1000 Genomes Phase I data (released Jan 2012) [11] were imputed using imputation on the iCOGS chip in a region of 500 kb around the novel modifier locus at 6p24. The boundaries were determined according to the linkage disequilibrium (LD) structure in the region based on HapMap data. The imputation was carried out using IMPUTE 2.2 [12]. SNPs with imputation information/accuracy r^2<0.30 were excluded in the analyses.

Quality control of DNA samples. Of 10,048 genotyped samples (Table S2), 742 were excluded because they did not meet the phenotypic eligibility criteria or had self-reported non-CEU ethnicity. Samples were then excluded for the following reasons: not female (XXY, XY), call rate <95%, low or high heterozygosity (P<10^{-5}), discordant genotypes from previous CIMBA genotyping efforts, or discordant duplicate samples. For duplicates with concordant phenotypic data, or in cases of cryptic monozygotic twins, only one of the samples was included. Cryptic duplicates for which phenotypic data indicated different individuals were all excluded. Samples of non-European ancestry were identified using multi-dimensional scaling, after combining the BRCA2 mutation carrier samples with the HapMap2 CEU, CHB, JPT and YRI samples using a set of 37,120 uncorrelated SNPs from the iCOGS array. Samples with ≥19% non-European ancestry were excluded (Figure S2). A total of 4,330 affected and 3,881 unaffected BRCA2 mutation carrier women of European ancestry from 42 studies remained in the analysis (Table S1), including 3,234 breast cancer cases and 3,490 unaffected carriers that were not in the discovery set.

BRCA1 and BCAC samples. Details of the sample collection, genotyping and quality control process for the BRCA1 and BCAC samples, are reported elsewhere [13,14].

Statistical methods

The associations between genotype and breast cancer risk were analyzed within a retrospective cohort framework with time to breast cancer diagnosis as the outcome [15]. Each BRCA2 carrier was followed until the first event: breast or ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last observation. Only those with a breast cancer diagnosis were considered as cases in the analysis. The majority of mutation carriers were recruited through genetic counseling centers where genetic testing is targeted at women diagnosed with breast or ovarian cancer and in particular to those diagnosed with breast cancer at a young age. Therefore, these women are more likely to be sampled compared to unaffected mutation carriers or carriers diagnosed with the disease at older ages. As a consequence, sampling was not random with respect to disease phenotype and standard methods of survival analysis (such as Cox regression) may lead to biased estimates of the associations [16]. We therefore conducted the analysis by modelling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes. This has been shown to provide unbiased estimates of the associations [15]. The implementation of the retrospective likelihoods has been described in detail elsewhere [15,17]. The associations between genotype and breast cancer risk were assessed using the 1d.f. degree of freedom score test statistic based on the retrospective likelihood [15]. In order to account for non-independence between relatives, an adjusted version of the score test was used in which the variance of the score was derived taking into account the correlation between the genotypes [18]. P-values were not adjusted using genomic control because there was little evidence of inflation. Inflation was assessed using the genomic inflation factor, λ. Since this estimate is dependent on sample size, we also calculated λ adjusted to 1000 affected and 1000 unaffected samples. Per-allele and genotype-specific hazard-ratios (HR) and 95% confidence intervals (CI) were estimated by maximizing the retrospective likelihood. Calendar-year and cohort-specific breast cancer incidences for BRCA2 were used [1]. All analyses were stratified by country of residence. The USA and Canada strata were further subdivided by self-reported Ashkenazi Jewish ancestry. The assumption of proportional hazards was assessed by fitting a model that included a genotype-by-age interaction term. Between-country heterogeneity was assessed by comparing the results of the main analysis to a model with country-specific log-HRs. A possible survival bias due to inclusion of prevalent cases was evaluated by re-fitting the model after excluding affected carriers that were diagnosed ≥5 years prior to study recruitment. The associations between genotypes and tumor subtypes were evaluated using an extension of the retrospective likelihood approach that models the association with two or more subtypes simultaneously [19]. To investigate whether any of the significant SNPs were associated with ovarian cancer risk for BRCA2 mutation carriers and whether the inclusion of ovarian cancer patients as unaffected subjects biased our results, we also analyzed the data within a competing risks framework and estimated HR simultaneously for breast and ovarian cancer using the methods described elsewhere [15]. Analyses were carried out in R using the GenABEL libraries [20] and custom-written software. The retrospective likelihood was modeled in the pedigree-analysis software MENDEL [21], as described in detail elsewhere [15].

TCGA analysis. Affymetrix SNP 6.0 genotype calls for normal (non-tumor) breast DNA were downloaded for all available individuals from The Cancer Genome Atlas in September 2011. Analyses were limited to the 401 individuals of European ancestry based on principal component analysis. Expression levels in breast tumor tissue were adjusted for the top two principal components, age, gender (there are some male breast cancer cases in TCGA), and average copy number across the gene in the tumor. Linear regression was then used to test for association between the SNP and the adjusted gene expression level for all genes within one megabase.

Gene set enrichment analysis. To investigate enrichment of genes associated with breast cancer risk, the gene-set enrichment approach was implemented using Versatile Gene-based Association Study [22] based on the ranked P-values from retrospective likelihood analysis. Association List Go Annotator was also used to prioritize gene pathways using functional annotation from gene ontology (GO) [23] to increase the power to detect association to a pathway, as opposed to individual genes in the pathway. Both analyses were corrected for LD between SNPs, variable gene size, and interdependence of GO categories.
Predicted absolute breast cancer risks by combined SNP profile. We estimated the absolute risks of developing breast cancer based on the joint distribution of SNPs associated with breast cancer for BRCA2 mutation carriers. The methods have been described elsewhere [24]. To construct the SNP profiles, we considered the single SNP from each region with the strongest evidence of association in the present dataset. We included all loci that had previously been found to be associated with breast cancer risk through GWAS in the general population and demonstrated associations with breast cancer risk for BRCA2 mutation carriers, and loci that had GWAS level of significance in the current study. We assumed that all loci in the profile were independent (i.e. they interact multiplicatively on BRCA2 breast cancer risk). Genotype frequencies were obtained under the assumption of Hardy-Weinberg Equilibrium. For each SNP, the effect of each allele was assumed to be consistent with a multiplicative model (log-additive). We assumed that the average, age-specific breast cancer incidences, over all associated loci, agreed with published breast cancer risk estimates for BRCA2 mutation carriers [1].

Results

The genomic inflation factor (λ) based on the 18,086 BRCA2 GWAS SNPs in the 6,724 BRCA2 mutation carriers who were not used in the SNP discovery set was 1.034 (λ adjusted to 1000 affected and 1000 unaffected: 1.010, Figure S3). Multiple variants were associated with breast cancer risk in the combined discovery and replication datasets (Figure S4). SNPs in three independent regions had P-values < 5 × 10−8; one was a region not previously associated with breast cancer.

The most significant associations were observed for known breast cancer susceptibility regions, rs2420946 (per allele P = 2 × 10−14) in FGFR2 and rs3803562 (P = 5.4 × 10−11) near TOX3 (Table 1). Breast cancer risk associations with other SNPs reported previously for BRCA2 mutation carriers are summarized in Table 1. In this larger set of BRCA2 mutation carriers, we also identified novel SNPs in the 12p11 (PTHLH), 5q11 (MAP3K1), and 9p21 (CDKN2A/B) regions with smaller P-values for association than those of previously reported SNPs. These novel SNPs were not correlated with the previously reported SNPs (r² < 0.14). For one of the novel SNPs identified in the discovery GWAS [2], ZNF365 rs16917302, there was weak evidence of association with breast cancer risk (P = 0.01); however, an uncorrelated SNP, rs17221319 (r² < 0.01), 54 kb upstream of rs16917302 had stronger evidence of association (P = 6 × 10−8).

One SNP, rs9348512 at 6p24 not known to be associated with breast cancer, had a combined P-value of association of 3.9 × 10−8 amongst all BRCA2 samples (Table 2), with strong evidence of replication in the set of BRCA2 samples that were not used in the discovery stage (P = 5.2 × 10−5). The minor allele of rs9348512 (MAF = 0.35) was associated with a 15% decreased risk of breast cancer among BRCA2 mutation carriers (per allele HR = 0.85, 95% CI 0.80–0.90) with no evidence of between-country heterogeneity (P = 0.78, Figure S5). None of the genotyped (n = 68) or imputed (n = 3,507) SNPs in these regions showed a stronger association with risk (Figure 1; Table S3), but there were 40 SNPs with P < 10−4 (pairwise r² ≥ 0.38 with rs9348512, with the exception of rs11526201 for which r² = 0.01, Table S3). The association with rs9348512 did not differ by 6174dIT mutation status (P for difference = 0.33), age (P = 0.39), or estrogen receptor (ER) status of the breast tumor (P = 0.41). Exclusion of prevalent breast cancer cases (n = 1,732) produced results (HR = 0.83, 95% CI 0.77–0.89, P = 3.40 × 10−7) consistent with those for all cases.

SNPs in two additional regions had P-values < 10−5 for breast cancer risk associations for BRCA2 mutation carriers (Table 2). The magnitude of associations for both SNPs was similar in the discovery and second stage samples. In the combined analysis of all samples, the minor allele of rs619373, located in FGF13 (Xq26.3), was associated with higher breast cancer risk (HR = 1.30, 95% CI 1.17–1.45, P = 3.1 × 10−6). The minor allele of rs184577, located in C1P1/B1-AS1 (2p22–p21), was associated with lower breast cancer risk (HR = 0.93, 95% CI 0.79–0.91, P = 3.6 × 10−7). These findings were consistent across countries (P for heterogeneity between country strata = 0.39 and P = 0.30, respectively; Figure S6). There was no evidence that the HR estimates for rs619373 and rs184577 change with age of the BRCA2 mutation carriers (P for the genotype-age interaction = 0.80 and P = 0.40, respectively) and no evidence of survival bias for either SNP (rs619373: HR = 1.35, 95% CI 1.20–1.53, P = 1.5 × 10−6 and rs184577: HR = 0.86, 95% CI 0.79–0.93, P = 2.0 × 10−4, after excluding prevalent cases). The estimates for risk of ER-negative and ER-positive breast cancer were not significantly different (P for heterogeneity between tumor sub-types = 0.79 and 0.67, respectively). When associations were evaluated under a competing risks model, there was no evidence of association with ovarian cancer risk for SNPs rs9348512 at 6p24, rs619373 in FGF13 or rs184577 at 2p22 and the breast cancer associations were virtually unchanged (Table S4).

Gene set enrichment analysis confirmed that strong associations exist for known breast cancer susceptibility loci and the novel loci identified here (gene-based P < 1 × 10−5). The pathways most strongly associated with breast cancer risk that contained statistically significant SNPs included those related to ATP binding, organ morphogenesis, and several nucleotide bindings (pathway-based P < 0.05).

To begin to determine the functional effect of rs9348512, we examined associations of expression levels of any nearby gene in breast tumors with the minor A allele. Using data from The Cancer Genome Atlas, we found that the A allele of rs9348512 was strongly associated with mRNA levels of GCNT2 in breast tumors (P = 7.3 × 10−5).

The hazard ratios for the percentiles of the combined genotype distribution of loci associated with breast cancer risk in BRCA2 mutation carriers were translated into absolute breast cancer risks under the assumption that SNPs interact multiplicatively. Based on our results for SNPs in FGFR2, TOX3, 12p11, 5q11, CDKN2A/B, LSP1, 8q24, ESR1, ZNF365, 3p24, 12q24, 5p12, 11q13 and also the 6p24 locus, the 5% of the BRCA2 mutation carriers at lowest risk were predicted to have breast cancer risks by age 80 in the range of 21–47% compared to 83–100% for the 5% of mutation carriers at highest risk on the basis of the combined SNP profile distribution (Figure 2). The breast cancer risk by age 50 was predicted to be 4–11% for the 5% of the carriers at lowest risk compared to 29–81% for the 5% at highest risk.

Discussion

In the largest assemblage of BRCA2 mutation carriers, we identified a novel locus at 6q24 that is associated with breast cancer risk, and noted two potential SNPs of interest at Xq26 and 2p22. We also replicated associations with known breast cancer susceptibility SNPs previously reported in the general population and in BRCA2 mutation carriers. For the 12p11 (PTHLH), 5q11 (MAP3K1), and 9p21 (CDKN2A/B), we found uncorrelated SNPs...

PLOS Genetics | www.plosgenetics.org 7 March 2013 | Volume 9 | Issue 3 | e1003173
<table>
<thead>
<tr>
<th>Chr (Nearby Genes)</th>
<th>Report Status</th>
<th>SNP</th>
<th>r²</th>
<th>Minor Allele</th>
<th>Previously Reported Results</th>
<th>ICOGS Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ref</td>
<td>Affected N</td>
</tr>
<tr>
<td>10q26 (FGFR2)</td>
<td>reported</td>
<td>n2981575</td>
<td>G</td>
<td>[2]</td>
<td>2,155</td>
<td>2,016</td>
</tr>
<tr>
<td></td>
<td>novel</td>
<td>n2420946</td>
<td>0.96 A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16q12 (TOX3)</td>
<td>reported</td>
<td>n3803662</td>
<td>A</td>
<td>[2]</td>
<td>2,162</td>
<td>2,026</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n10771399</td>
<td>G</td>
<td>[34]</td>
<td>3,798</td>
<td>3,314</td>
</tr>
<tr>
<td>12p11 (PTHLH)</td>
<td>reported</td>
<td>n27633</td>
<td>0.05 C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5q11 (MAP3K1)</td>
<td>reported</td>
<td>n889312</td>
<td>C</td>
<td>[24]</td>
<td>2,840</td>
<td>2,282</td>
</tr>
<tr>
<td></td>
<td>novel</td>
<td>n1688613</td>
<td>0.14 C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9p21 (CDKN2A/B)</td>
<td>reported</td>
<td>n1011970</td>
<td>A</td>
<td>[34]</td>
<td>3,807</td>
<td>3,316</td>
</tr>
<tr>
<td></td>
<td>novel</td>
<td>n10995163</td>
<td>0.00 A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11p15 (LSPI1)</td>
<td>reported</td>
<td>n3817198</td>
<td>G</td>
<td>[24]</td>
<td>3,266</td>
<td>2,636</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n13281615</td>
<td>G</td>
<td>[24]</td>
<td>3,338</td>
<td>2,723</td>
</tr>
<tr>
<td>8q24</td>
<td>reported</td>
<td>n4733664</td>
<td>0.00 A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>novel</td>
<td>n13039229</td>
<td>0.00 C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6q25 (ESR1)</td>
<td>reported</td>
<td>n9397435</td>
<td>G</td>
<td>[35]</td>
<td>3,809</td>
<td>3,316</td>
</tr>
<tr>
<td></td>
<td>novel</td>
<td>n2253407</td>
<td>0.01 A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10q21 (ZNF365)</td>
<td>reported</td>
<td>n16917302</td>
<td>C</td>
<td>[5]</td>
<td>3,807</td>
<td>3,315</td>
</tr>
<tr>
<td></td>
<td>novel</td>
<td>n17221319</td>
<td>0.00 A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3p24 (SLC4A7, NEX10)</td>
<td>reported</td>
<td>n4973768</td>
<td>A</td>
<td>[24]</td>
<td>3,370</td>
<td>2,783</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n12902114</td>
<td>G</td>
<td>[34]</td>
<td>2,530</td>
<td>2,342</td>
</tr>
<tr>
<td>5p12</td>
<td>reported</td>
<td>n10941679</td>
<td>G</td>
<td>[24]</td>
<td>3,263</td>
<td>2,591</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n614367</td>
<td>A</td>
<td>[34]</td>
<td>3,789</td>
<td>3,307</td>
</tr>
<tr>
<td>11q13</td>
<td>reported</td>
<td>n614367</td>
<td>A</td>
<td>[34]</td>
<td>3,789</td>
<td>3,307</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n11249433</td>
<td>G</td>
<td>[35]</td>
<td>3,423</td>
<td>2,827</td>
</tr>
<tr>
<td>17q23 (STXBP4, COX17)</td>
<td>reported</td>
<td>n6504950</td>
<td>A</td>
<td>[24]</td>
<td>3,401</td>
<td>2,813</td>
</tr>
<tr>
<td>19p13 (MERIT40)</td>
<td>reported</td>
<td>n8170</td>
<td>A</td>
<td>[5]</td>
<td>3,665</td>
<td>3,086</td>
</tr>
<tr>
<td>9q31</td>
<td>reported</td>
<td>n865686</td>
<td>C</td>
<td>[34]</td>
<td>3,799</td>
<td>3,312</td>
</tr>
<tr>
<td>10q22 (ZMM1)</td>
<td>reported</td>
<td>n704010</td>
<td>A</td>
<td>[34]</td>
<td>3,761</td>
<td>3,279</td>
</tr>
</tbody>
</table>

1 Reporting status of the SNP is either previously reported or novel to this report.
2 p-value was calculated based on the 1-degree of freedom score test statistic.
3 SNP rs311499 could not be designed onto the iCOGS array. A surrogate (r² = 1.0), rs311498, was included, however, and reported here.
4 Stronger associations were originally reported for the SNP, assuming a dominant or recessive model of the ‘risk allele’.

doi:10.1371/journal.pgen.1003173.t001
Table 2. Breast cancer hazard ratios (HR) and 95% confidence intervals (CI) of novel breast cancer loci with P-values of association <10^{-5} among BRCA2 mutation carriers.

<table>
<thead>
<tr>
<th>SNP rs No. Chr (Nearby Genes)</th>
<th>Genotype</th>
<th>Affected No. (%)</th>
<th>Unaffected No. (%)</th>
<th>HR (95% CI)</th>
<th>p-value</th>
<th>Affected No. (%)</th>
<th>Unaffected No. (%)</th>
<th>HR (95% CI)</th>
<th>p-value</th>
<th>Affected No. (%)</th>
<th>Unaffected No. (%)</th>
<th>Unaffected MAF</th>
<th>HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs9346512 Chr6</td>
<td>CC</td>
<td>390 (46.4)</td>
<td>248 (38.3)</td>
<td>1.00</td>
<td></td>
<td></td>
<td>1392 (43.0)</td>
<td></td>
<td></td>
<td></td>
<td>1640 (42.3)</td>
<td></td>
<td>0.35</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>CA</td>
<td>368 (43.8)</td>
<td>299 (46.2)</td>
<td>0.81 (0.67–0.96)</td>
<td></td>
<td>1515 (43.4)</td>
<td>1432 (44.3)</td>
<td>0.92 (0.83–1.01)</td>
<td>1883 (43.5)</td>
<td>1731 (44.6)</td>
<td>0.89 (0.82–0.97)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>82 (9.8)</td>
<td>100 (15.5)</td>
<td>0.55 (0.42–0.74)</td>
<td></td>
<td>368 (10.5)</td>
<td>410 (12.7)</td>
<td>0.72 (0.62–0.84)</td>
<td>450 (10.4)</td>
<td>510 (12.1)</td>
<td>0.68 (0.59–0.78)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>per allele</td>
<td>0.76 (0.67–0.87)</td>
<td>2.6×10^{-5}</td>
<td></td>
<td></td>
<td>0.87 (0.81–0.93)</td>
<td>5.2×10^{-5}</td>
<td></td>
<td></td>
<td>0.85 (0.80–0.90)</td>
<td>3.9×10^{-8}</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs619373 ChrX</td>
<td>GG</td>
<td>693 (75.8)</td>
<td>568 (87.8)</td>
<td>1.00</td>
<td></td>
<td></td>
<td>2882 (82.7)</td>
<td></td>
<td></td>
<td></td>
<td>3575 (82.6)</td>
<td></td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>GA</td>
<td>143 (15.7)</td>
<td>78 (12.1)</td>
<td>1.43 (1.13–1.80)</td>
<td></td>
<td>583 (16.7)</td>
<td>439 (13.6)</td>
<td>1.25 (1.10–1.43)</td>
<td>726 (16.8)</td>
<td>517 (13.3)</td>
<td>1.29 (1.15–1.45)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>4 (8.5)</td>
<td>1 (0.1)</td>
<td>2.01 (0.50–8.06)</td>
<td></td>
<td>21 (0.6)</td>
<td>11 (0.3)</td>
<td>2.09 (1.09–4.03)</td>
<td>25 (0.6)</td>
<td>12 (0.3)</td>
<td>1.99 (1.16–3.41)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>per allele</td>
<td>1.43 (1.15–1.78)</td>
<td>3.0×10^{-3}</td>
<td></td>
<td></td>
<td>1.27 (1.12–1.44)</td>
<td>2.0×10^{-4}</td>
<td></td>
<td></td>
<td>1.30 (1.17–1.45)</td>
<td>3.1×10^{-5}</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs184577 Chr2</td>
<td>GG</td>
<td>520 (61.9)</td>
<td>368 (56.9)</td>
<td>1.00</td>
<td></td>
<td></td>
<td>2104 (60.3)</td>
<td></td>
<td></td>
<td></td>
<td>2624 (60.6)</td>
<td></td>
<td>0.25</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>GA</td>
<td>278 (33.1)</td>
<td>234 (36.2)</td>
<td>0.86 (0.71–1.03)</td>
<td></td>
<td>1212 (34.7)</td>
<td>1231 (38.1)</td>
<td>0.83 (0.75–0.92)</td>
<td>1490 (34.4)</td>
<td>1465 (37.8)</td>
<td>0.83 (0.76–0.91)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>42 (5.0)</td>
<td>45 (7.0)</td>
<td>0.67 (0.46–0.96)</td>
<td></td>
<td>174 (5.0)</td>
<td>179 (5.5)</td>
<td>0.80 (0.64–0.99)</td>
<td>216 (5.0)</td>
<td>224 (5.8)</td>
<td>0.77 (0.64–0.93)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>per allele</td>
<td>0.84 (0.73–0.97)</td>
<td>1.5×10^{-2}</td>
<td></td>
<td></td>
<td>0.86 (0.79–0.93)</td>
<td>8.6×10^{-3}</td>
<td></td>
<td></td>
<td>0.85 (0.79–0.91)</td>
<td>3.6×10^{-5}</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1P-value was calculated based on the 1-degree of freedom score test.
doi:10.1371/journal.pgen.1003173.t002
that had stronger associations than the originally identified SNP in the breast cancer susceptibility region that should be replicated in the general population. In BRCA2 mutation carriers, evidence for a breast cancer association with genetic variants in PTHLH has been restricted previously to ER-negative tumors [25]; however, the novel susceptibility variant we reported here was associated with risk of ER+ and ER- breast cancer.

The novel SNP rs9348512 (6p24) is located in a region with no known genes (Figure 1). C6orf218, a gene encoding a hypothetical protein LOC221718, and a possible tumor suppressor gene, TFAP2A, are within 100 kb of rs9348512. TFAP2A encodes the AP-2α transcription factor that is normally expressed in breast ductal epithelium nuclei, with progressive expression loss from normal, to ductal carcinoma in situ, to invasive cancer [26,27]. AP-2α also acts as a tumor suppressor via negative regulation of MYC [28] and augmented p53-dependent transcription [29]. However, the minor allele of rs9348512 was not associated with gene expression changes of TFAP2A in breast cancer tissues in The Cancer Genome Atlas (TCGA) data; this analysis might not be informative since expression of TFAP2A in invasive breast tissue is low [26,27]. Using the TCGA data and a 1 Mb window, expression changes with genotypes of rs9348512 were observed for GCNT2, the gene encoding the enzyme for the blood group I antigen glucosaminyl (N-acetyl) transferase 2. GCNT2, recently found to be overexpressed in highly metastatic breast cancer cell lines [30] and basal-like breast cancer [31], interacts with TGF-β to promote epithelial-to-mesenchymal transition, enhancing the metastatic potential of breast cancer [31]. An assessment of alterations in expression patterns in normal breast tissue from BRCA2 mutation carriers by genotype are needed to further evaluate the functional implications of rs9348512 in the breast tumorigenesis of BRCA2 mutation carriers.

To determine whether the breast cancer association with rs9348512 was limited to BRCA2 mutation carriers, we compared results to those in the general population genotyped by BCAC and to BRCA1 mutation carriers in CIMBA. No evidence of an associations between rs9348512 and breast cancer risk was observed in the general population (OR = 1.00, 95% CI 0.98–1.02, P = 0.74) [14], nor in BRCA1 mutation carriers (HR = 0.99, 95% CI 0.94–1.04, P = 0.75) [13]. Stratifying cases by ER status, there was no association observed with ER-subtypes in either the general population or among BRCA1 mutation carriers (BCAC: ER positive P = 0.89 and ER negative P = 0.60; CIMBA BRCA1: P = 0.49 and P = 0.99, respectively). For the two SNPs associated with breast cancer with P<10^-5, neither rs619373, located in FGF13 (Xq26.3), nor rs184577, located in CYP1B1-AS1 (2p22-p21), was associated with breast cancer risk in the general population [14] or among BRCA1 mutation carriers [13]. The narrow CIs for the overall associations in the general population and in BRCA1 mutation carriers rule out associations of magnitude similar to those observed for BRCA2 mutation carriers. The consistency of the association in the discovery and replication stages and by country, the strong quality control measures and filters, and the clear cluster plot for rs9348512 suggest that our results constitute the discovery of a novel breast cancer susceptibility locus specific to BRCA2 mutation carriers rather than a false positive finding. Replicating this SNP in an even larger population of BRCA2 mutation carriers would be ideal, but not currently
possible because we know of no investigators with appropriate data and germline DNA from BRCA2 mutation carriers who did not contribute their mutation carriers to iCOGS. However, CIMBA studies continue to recruit individuals into the consortium.

rs9348512 (6p24) is the first example of a common susceptibility variant identified through GWAS that modifies breast cancer risk specifically in BRCA2 mutation carriers. Previously reported BRCA2-modifying alleles for breast cancer, including those in FGFR2, TOX3, MAP3K1, LSP1, 8q24, ESR1, ZNF365, 3p24, 12q24, 3p12, 11q13 and the newly identified BRCA2 modifier locus at 6p24. The figure shows the risks at the 5th and 95th percentiles of the combined genotyped distribution as well as minimum, maximum and average risks.

doi:10.1371/journal.pgen.1003173.g002

Figure 2. Predicted breast cancer risks for BRCA2 mutation carriers by the combined SNP profile distributions. Based on the known breast cancer susceptibility loci at FGFR2, TOX3, 12p11, 5q11, CDKN2A/B, LSP1, 8q24, ESR1, ZNF365, 3p24, 12q24, 3p12, 11q13 and the newly identified BRCA2 modifier locus at 6p24. The figure shows the risks at the 5th and 95th percentiles of the combined genotyped distribution as well as minimum, maximum and average risks.

Supporting Information

Figure S1 Cluster plots for SNPs (A.) rs9348512, (B.) rs619373, and (C.) rs184577. (TIF)

Figure S2 Multidimensional scaling plots of the top two principal components of genomic ancestry of all eligible BRCA2 iCOGS samples plotted with the HapMap CEU, ASI, and YRI samples: (A.) samples from Finland and BRCA2 617delIT carriers highlighted, and (B.) samples, indicated in red, with >19% non-European ancestry were excluded. (TIF)

Figure S3 Quantile–quantile plot comparing expected and observed distributions of P-values. Results displayed (A) for the complete sample, (B) after excluding samples from the GWAS discovery stage, and (C) for the complete sample and a set of SNPs from the iCOGS array that were selected independent from the results of the BRCA2 mutation carriers. (TIF)

Figure S4 Manhattan plot of P-values by chromosomal position for 18,086 SNPs selected on the basis of a previously published genome-wide association study of BRCA2 mutation carriers. Breast cancer associations results based on 4,330 breast cancer cases and 3,881 unaffected BRCA2 carriers. (TIF)

Figure S5 Forest plot of the country-specific, per-allele hazard ratios (HR) and 95% confidence intervals for the association between breast cancer and rs9348512 genotypes. (TIF)

Figure S6 Forest plot of the country-specific, per-allele hazard ratios (HR) and 95% confidence intervals for the association with breast cancer for (A.) rs619373 and (B.) rs184577 genotypes. (TIF)

Table S1 Quality control filtering steps for BRCA2 mutation carriers and SNPs on the COGs array. (DOC)

Table S2 Description of breast cancer affected and unaffected BRCA2 carriers included in the final analysis of the COGs array SNPs. (DOC)

Table S3 Breast cancer hazards ratios (HR) and 95% confidence intervals (CI) for all SNPs with P<10^{-5} in a 500 Mb region around rs9348512 on 6p24 among BRCA2 mutation carriers. (DOC)

Table S4 Associations with SNPs at 6p24, FGFI3 and 2p22 and breast and ovarian cancer risk using a competing risk analysis model. (DOC)

Acknowledgments

iCOGS: We acknowledge the contributions of Kyriaki Michailidou, Jonathan Tyrer, and Ali Amin Al Olama to the iCOGS statistical analyses and Shahnaz Ahmed, Melanie J. Maranian, and Catherine S. Healey for their contributions to the iCOGS genotyping quality control process.

Consortium of Modifiers of BRCA1/2 Associations (CIMBA): The authors would like to acknowledge the contribution of the staff of the genotyping unit under the supervision of Dr. Sylvie LaBoissière as well as Frédéric Robidoux from the McGill University and Génome Quebec Innovation Centre.

Breast Cancer Association Consortium (BCAC): We thank all the individuals who took part in these studies and all the researchers,
clinicians, technicians, and administrators who have enabled this work to be carried out. Amsterdam Breast Cancer Study (ABCs): We thank Annejiek Broeks, Sten Cornelissen, Richard van Hien, Linde Braaf, Sennu Verhoef, Laura van ‘t Veer, Emiel Rutgers, Ellen van der Schoot, and Femke Atsum.

Bavarian Breast Cancer Cases and Controls (BBCG): We thank Lothar Hassel, Sonja Oesser, Silke Landrath, and Reiner Strick.

British Breast Study (BBS): We thank Eileen Williams, Elaine Ryder-Mills, and Kara Sargs.

Breast Cancer Family Registry (BCFR) Studies: Samples from the NC-BCFR were processed and distributed by the Correll Institute for Medical Research. We wish to thank members and participants in the Breast Cancer Family Registry for their contributions to the study. The ABCFS would like to also thank Maggie Angelakos, Judy Maskiell, and Elaine Wilkins. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the BCFR.


Breast Cancer in Galway Genetic Study (BIGGS): We thank Niall McInerney, Gabrielle Colleran, Andrew Rowan, and Angela Jones.

BRCA-gene mutations and breast cancer in South African women (BMBSA): We wish to thank the families who contribute to the BMBSA study.

Beckman Research Institute of the City of Hope (BRICOH): We thank Greg Wilhoite, Yuan Chun Ding, Linda Steele, and Elaine Wilkins for their work in participant enrollment and biospecimen and data management.

Breast Cancer Study of the University Clinic Heidelberg (BUSCH): We thank Peter Bugert, Medical Faculty Mannheim.

Copenhagen General Population Study (CGPS): We appreciate the staff and participants of the Copenhagen General Population Study. For the excellent technical assistance, we thank Dorte Huldahl Anthonsen, Maria Birna Arnadottir, Anne Bank, and Dorte Kjeldgaard Hansen.

Spanish National Centre (CNIO): We wish to thank Alicia Barroso, Rosario Alonso, and Guillermo Pita for their assistance.

Spanish National Centre Breast Cancer Study (CNIO-BCS): We thank Charo Alonso, Guillermo Pita, Nuria Alvarez, Daniel Herrero, Primitiva Menendez, José Ignacio Arias Pérez, Pilar Zamora, the Broeks, Sten Cornelissen, Richard van Hien, Linde Braaf, Senno Verhoef, We thank Peter Bugert, Medical Faculty Mannheim.

Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE): Douglas F. Easton is the PI of the study. EMBRACE Coordinating Centres are: Collaborating Centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the BCFR.

German Consortium of Hereditary Breast and Ovarian Cancer (GG-HBCO): We are very thankful to all family members who participated in this study; Wolfram Heinritz, Center Leipzig, and Dieter Schäfer, Center Frankfurt, for providing DNA samples; and Juliane Kohler for excellent technical assistance; as well as Heide Hellebrand, Sabine Euker, and GG-HE.

Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO): National Cancer Genetics Network «UNICANCER Genetic Groups», France. We wish to thank all the GEMO collaborating groups for their contribution to this study. GEMO Collaborating Centers are: Coordinating Centre, Cambridge: Susan Ellis, Doug Fearon, Daniel Pinkerton, and Karin Sargus. We thank Alicia Barroso, Rosario Alonso, and Guillermo Pita for their assistance.

Germen Onemaging stain de van de werkgroep Hereditair Borstkanker Onderzoek Nederland (DNA HEBON): DNA HEBON consists of the following Collaborating Centers: Coordinating center: Netherlands Cancer Institute, Amsterdam, NL: M.A. Rookus, F.B.L. Hogervorst, F.E. van Leeuwen, S. Verhoef, M.K. Schmitt, J.L. de Lange; Erasmus Medical Center, Rotterdam, NL: J.M. Collée, M.J.W. van den Ouweland, M.J. Hoornweg, C. Seynaeve, M.J. van den Berken; Leiden University Medical Center, NL: C.G. van Asperen, J.T. Wijn, R.A. Tolenaar, P. Devilee, T.C.T.E.F. van Cronenburg; Radboud University Nijmegen Medical Center, NL: C.M. Kets, A.R. Mensenkamp; University Medical Center Utrecht, NL: M.G.E.M. Ausens, R.B. van der Luijt; Amsterdam Medical Center, NL: C.M. Aalst, T.A.M. van Oo; VU University Medical Center, Amsterdam, NL: J.J.P. Gilé, Q. Waisfisz, H.E.J. Meijers-Heijboer; University Hospital Maastricht, NL: E.B. Gómez-García, M.J. Blok; University Medical Center Groningen, NL: J.C. Oosterwijk, A.H. van der Hout, M.J. Mourits, G.H. de Bock. The Netherlands Foundation for the detection of hereditary tumours, Leiden, NL: H.F. Van den.

Gene Environment Interaction and Breast Cancer in Germany (GENICA): The GENICA network: Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tubingen, Germany; [CJ, Hiltrud Brauch], Department of Internal Medicine, Evangelische Krankenhaus Bonn eGmbH, Johanniter Krankenhaus, Bonn, Germany; [Yon-Dschun Ko, Christian Baisch], Institute of Pathology, University of Bonn, Germany [Hand-Peter Fischer], Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany [UH]; and Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (ifa), Bochum, Germany [Thomas Bruning, Beate Pesch, Sylvia Rabstein, Anne Spichiger, VH].

Hospital Clinico San Carlos (HCSC): We acknowledge Alicia Tosar for her technical assistance.

Helsinki Breast Cancer Study (HEBCS): HEBCS would like to thank Drs. Kristiina Aittomäki, Clark Blomqvist and Kirsimari Aaltonen, and Taru A. Muranen and RN Irja Erkkila for their help with the HEBCS data and samples.

Hannover-Minsk Breast Cancer Study (HMBCS): We thank Natalia Bogdanova, Natalia Antonenkov, Hans Christiansen, and Peter Hilleron as collaborators.

Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia (HRBCP): We wish to thank Hong Kong Sanatorium and Hospital for their continual support.

Molecular Genetic Studies of Breast- and Ovarian Cancer in Hungary (HUNBOCS): We wish to thank the Hungarian Breast and Ovarian Cancer Study Group members [Janos Papp, Aniko Bozink, Kristof Arvai, Judit Franko, Maria Balogh, Gabriella Varga, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary], and the clinicians and patients for their contributions to this study.

University Hospital Vall d’Hebron (HVH): We thank the study staff and participants.

Interdisciplinary HEalth Research Internal Team BreaSt Cancer susceptibility (INHERIT): We would like to thank Dr. Martine Dumontier of Marie Tranchant for sample management and skillful technical assistance.

Kuopio Breast Cancer Project (KBCP): We thank Eija Myöhänen and Helena Kemilainen.

Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab/AOCS): We thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study for their contributions to this resource, and the many families who contribute to kConFab.

Leuven Multidisciplinary Breast Centre (LMBC): We thank Gillian Peuteman, Dominiek Smeets, Thomas Van Brussel, and Kathleen Corthouts.

Mammary Carcinoma Risk Factor Investigation (MARIE): We thank Dieter Flech-Jans, Rebecca Hein, Stefan Nickels, Mahlabett Gelik, Sabine Behrens, and Ursula Elber.

Milan Breast Cancer Study Group (MBCSG): We thank Daniela Zafferani of the Fondazione Istituto Nazionale Tumori, Milan, Italy and the personnel of the CGT laboratory at IFOM-IEO Campus, Milan, Italy.

Montreal Gene-Environment Breast Cancer Study (MTLGEBCS): We thank Marieine Tranchant (Cancer Genomics Laboratory, CRCHUQ), Marie Arvai, and Kristina Turgone, St. Ghislain Hospital, and Lea Heguy (McGill University Health Center, Royal Victoria Hospital; McGill University) for DNA extraction, sample management, and skillful technical assistance.

General Hospital Vienna (MUV): We thank the study staff and participants.

National Israeli Cancer Control Center (NIIICC): We wish to thank the NIIICC National Familial Cancer Consultation Service team led by Sara Dishon, the lab team led by Dr. Flavio Lejbkowicz, and the research field operations team led by Dr. Milla Pinchuck.

Oulu Breast Cancer Study (OBCS): We thank Katri Pylkas, Arja Jukkola-Vuorinen, Mervi Grip, Saira Kauppiä, Mertie Otsuka, and Kari Mononen.

Ontario Cancer Genetics Network (OCGN): We thank the study staff and participants.

University Medical Centre Medical Breast Cancer Study (ORIGO): We thank E. Krol-Warmerdam, and J. Blom for patient accrual, administering questionnaires, and managing clinical information. The LUMC survival data were retrieved from the Leiden hospital-based cancer registry system (ONCODC) with the help of Dr. J. Molenaar.

The Ohio State University Comprehensive Cancer Center (OSUCCG): Kevin Sweet, Caroline Craven, and Michelle O’Connor were instrumental in accrual of study participants, ascertainment of medical records and database management. Samples were processed by the OSU Human Genetics Sample Bank.

Odense University Hospital (OUH): We thank the study staff and participants.

Università di Pisa (PBS): We thank the study staff and participants.

The U. S. National Cancer Institute Polish Breast Cancer Study (PBCS): We thank the study collaborators Drs. Louise Brinton, Mark Sherman, Stephen Chanoock, Neolina Szeszenia-Dabrowska, Beata Peplonska, and Witold Zatorski, as well as Pei Chao and Michael Stagner, for their data management support.

Rotterdam Breast Cancer Study (RBCS): We thank Petra Bos, Jamet Blom, Ellen Crepin, Elisabette Huiskens, Annette Heemskerk, and the Erasmus MC Family Cancer Clinic.

Sheffield Breast Cancer Study (SBCS): We thank Sue Higham, Helen Crump, and Dan Crean.

South East Asian Breast Cancer Association Study (SEABASS): We would like to thank Yip Cheng Har, Nar Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan, and all the research nurses, research assistants, and doctors involved in the MyBeCa Study for assistance in patient recruitment, data collection, and sample preparation. In addition, we thank Philip Isu, Sng Jen-Hwei, and Sharifah Nor Akmal for contributing samples from the Singapore Breast Cancer Study and the HUKM-HKL Study respectively.

Study of Epidemiology and Risk Factors in Cancer Heredity (SEARCH): We thank the SEARCH and EPIC teams.

Sheba Medical Centre (SMC): SMC team wishes to acknowledge the assistance of the Meirav Comprehensive breast cancer center team at the Sheba Medical Center for assistance in this study.

Swedish Breast Cancer Association (SWE-BRCA): Swedish scientists participating as SWE-BRCA collaborators are: from Lund University and University Hospital: Ake Borg, Häkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; from Umeå University Hospital: A˚ke Borg, Ha˚kan Olsson, Helena Jernstro¨m, Karin Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Öfverholm, Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; from Linko¨ping University Hospital: A˚ke Borg, Ha˚kan Olsson, Helena Jernstro¨m, Karin Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; from Sahlgrenska University Hospital: Anna Öfverholm, Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; from Stockholm University Hospital: Anna Svensson, Joakim Sandstrom, Kajsa Olsson, Per-Anders Hagmar, and Anna-Lena Pettersson.

The University of Chicago Center for Clinical Cancer Genetics and Global Health (UCHICAGO): We wish to thank
References


